药师主导的远程医疗减处方干预在痴呆共病患者中的预试验
本研究在两家健康系统开展预试验,纳入服用≥7种药物的痴呆患者及其照护伙伴69对,随机分为立即干预组与延迟3个月对照组。药师通过远程医疗进行减处方干预,结果显示干预可行,基层医生对82%的首条信息作出回应并同意98%的建议,干预组停药比例高于对照组。
要点
- 药师远程减处方干预在痴呆多重用药患者中具有可行性。
- 基层医生对药师建议的接受度很高(回应82%,同意98%)。
- 3个月时干预组81%患者至少停用1种药物,对照组为50%。
核心结论
- 药师主导的远程医疗减处方干预虽然复杂,但在痴呆多重用药患者中可行,并可能减轻其用药负担。
- 为契合患者-照护伙伴目标,药师同时给出了减处方和新增药物的建议。
研究设计与样本
- 预试验于2021年5月至2022年在两家健康系统开展,纳入基层医疗中服用≥7种药物的痴呆患者及照护伙伴。
- 共69对 dyad 入组,随机分为立即接受药师远程医疗干预组(34对)和延迟3个月对照组(35对)。
主要发现
- 干预组27/34(79%)和对照组28/35(80%)完成了干预。
- 93%的访视耗时超过20分钟,62%需要多次后续互动。
- 基层医生回应了82%的药师首条信息,并同意了98%的建议。
- 3个月时,干预组22例(81%)和对照组14例(50%)至少停用1种药物;干预组21例(78%)和对照组12例(43%)至少新增1种药物。
- 干预组平均药物数减少0.6(SD 3.4),对照组减少0.2(SD 1.7);MRCI在干预组降低1.0(±12.4)分,对照组升高1.2(±12.9)分,被认为无临床意义。
关键数值与推荐
- 入组标准为痴呆患者服用≥7种药物且有照护伙伴参与。
- 主要可行性指标包括入组率、干预完成率、药师耗时和基层医生对建议的接受度。
临床怎么用
- 药师可通过远程医疗与基层医生协作,针对痴呆多重用药患者开展以目标为导向的减处方和处方优化。
- 干预需预留多次互动时间,多数访视超过20分钟。
局限性
- 本研究为预试验,样本量小(69对),主要评估可行性而非临床疗效。
- MRCI变化无临床意义,FCMAHS评分变化在两组间差异未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with dementia (PLWD) have complex medication regimens, exposing them to increased risk of harm. Pragmatic deprescribing strategies that align with patient-care partner goals are needed. METHODS: A pilot study of a pharmacist-led intervention to optimize medications with patient-care partner priorities, ran May 2021-2022 at two health systems. PLWD with ≥7 medications in primary care and a care partner were enrolled. After an introductory mailing, dyads were randomized to a pharmacist telehealth intervention immediately (intervention) or delayed by 3 months (control). Feasibility outcomes were enrollment, intervention completion, pharmacist time, and primary care provider (PCP) acceptance of recommendations. To refine pragmatic data collection protocols, we assessed the Medication Regimen Complexity Index (MRCI; primary efficacy outcome) and the Family Caregiver Medication Administration Hassles Scale (FCMAHS). RESULTS: 69 dyads enrolled; 27 of 34 (79%) randomized to intervention and 28 of 35 (80%) randomized to control completed the intervention. Most visits (93%) took more than 20 min and required multiple follow-up interactions (62%). PCPs responded to 82% of the pharmacists' first messages and agreed with 98% of recommendations. At 3 months, 22 (81%) patients in the intervention and 14 (50%) in the control had ≥1 medication discontinued; 21 (78%) and 12 (43%), respectively, had ≥1 new medication added. The mean number of medications decreased by 0.6 (3.4) in the intervention and 0.2 (1.7) in the control, reflecting a non-clinically meaningful 1.0 (±12.4) point reduction in the MRCI among intervention patients and a 1.2 (±12.9) point increase among control. FCMAHS scores decreased by 3.3 (±18.8) points in the intervention and 2.5 (±14.4) points in the control. CONCLUSION: Though complex, pharmacist-led telehealth deprescribing is feasible and may reduce medication burden in PLWD. To align with patient-care partner goals, pharmacists recommended deprescribing and prescribing. If scalable, such interventions may optimize goal-concordant care for PLWD.
引用
- Green AR, Quiles R, Daddato AE, et al. Pharmacist-led telehealth deprescribing for people living with dementia and polypharmacy in primary care: A pilot study. J Am Geriatr Soc. 2024. PMID: 38488757. doi:10.1111/jgs.18867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。